Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study-Reference-Cited by-同舟云学术

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

Published:2020-11 Issue:11 Volume:21 Page:1513-1525
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Fizazi Karim,Kramer Gero,Eymard Jean-Christophe,Sternberg Cora N,de Bono Johann,Castellano Daniel,Tombal Bertrand,Wülfing Christian,Liontos Michael,Carles Joan,Iacovelli Roberto,Melichar Bohuslav,Sverrisdóttir Ásgerður,Theodore Christine,Feyerabend Susan,Helissey Carole,Oudard Stéphane,Facchini Gaetano,Poole Elizabeth M,Ozatilgan Ayse,Geffriaud-Ricouard Christine,Bensfia Samira,de Wit Ronald

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology;Nuhn;Eur Urol,2019

2. Sequential use of new agents (NAs) after docetaxel (DOC) first line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): a pooled-analysis of the published studies;Maines;Proc Am Soc Clin Oncol,2015

3. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment;Attard;J Clin Oncol,2018

4. Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer;Anido-Herranz;Clin Transl Oncol,2019

5. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers;Value in Health;2024-07

2. Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review;Frontiers in Oncology;2024-04-15

3. Fabrication of hyaluronic acid-altered gold complex delivery for head and neck squamous cell carcinoma therapy with high antitumor efficacy and low in vivo toxicity;Journal of Photochemistry and Photobiology B: Biology;2024-04

4. Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology;Current Oncology;2024-02-15

5. How to Integrate Prostate Cancer Biomarkers in Urology Clinical Practice: An Update;Cancers;2024-01-11